# MK-2206 for Recurrent Malignant Glioma

> **NCT01249105** · PHASE2 · WITHDRAWN · sponsor: **Dana-Farber Cancer Institute**

## Conditions studied

- Malignant Glioma

## Interventions

- **DRUG:** MK-2206

## Key facts

- **NCT ID:** NCT01249105
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Merck (supplier of study drug \& funding) has undergone a large reprioritization, in which they had to terminate many oncology trials, including this one.
- **Last updated:** 2016-03-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01249105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01249105, "MK-2206 for Recurrent Malignant Glioma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01249105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*